Arcede Pharma is a pharmaceutical company. The company conducts research and development in the field of chronic obstructive pulmonary disease, also abbreviated as COPD, and severe asthma. The company's product portfolio includes medicines intended for the treatment and relief of the above ailments. The largest activity is found within the Nordic market. The company was created via a spin-off of Respiratorius in 2022 and today has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Christer Fåhraeus | 11,24 | 11,24 | 2023-06-28 |
| Avanza Pension | 5,92 | 5,92 | 2023-06-28 |
| Valcuria Holding AB | 3,86 | 3,86 | 2023-06-28 |
| Ben Hayes | 2,34 | 2,34 | 2023-06-28 |
| Hans Harvig | 1,72 | 1,72 | 2023-06-28 |
| Hans Jönsson | 1,71 | 1,71 | 2023-06-28 |
| Linnart Shabo | 1,70 | 1,70 | 2023-06-28 |
| Nordnet Pensionsförsäkring | 1,58 | 1,58 | 2023-06-28 |
| Sven Niklas Anders Axelsson | 1,17 | 1,17 | 2023-06-28 |
| Andreas Bylin | 1,14 | 1,14 | 2023-06-28 |
2023-11-10 Delårsrapport 2023-Q3
2024-02-12 Bokslutskommuniké 2023